iSpecimen Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
iSpecimen Inc. (ISPC) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$2.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-14
- iSpecimen Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$4.06M.
- iSpecimen Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$1.10M.
- iSpecimen Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$253.78K.
- iSpecimen Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$11.55M.
- iSpecimen Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $5.00M.
- iSpecimen Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$465.26K.
- iSpecimen Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$12.97M.
- iSpecimen Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$12.43M, a 145.96% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.47M 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | -$4.06M 10-Q · filed 2026-05-18 | |||
| 2025-12-31 | $5.00M 10-K · filed 2026-04-01 | |||
| 2025-09-30 | $904.35K 10-Q · filed 2025-11-17 | |||
| 2025-06-30 | -$1.29M 10-Q · filed 2026-08-14 | |||
| 2025-03-31 | -$1.10M 10-Q · filed 2026-05-18 | |||
| 2024-12-31 | -$465.26K 10-K · filed 2026-04-01 | |||
| 2024-09-30 | -$591.81K 10-Q · filed 2025-11-17 | |||
| 2024-06-30 | -$192.42K 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$253.78K 10-Q · filed 2025-05-19 | |||
| 2023-12-31 | -$12.97M 10-K · filed 2025-04-14 | |||
| 2023-09-30 | -$12.59M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$13.30M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | -$11.55M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$12.43M 10-K · filed 2024-03-13 | |||
| 2022-09-30 | -$7.08M 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | -$4.05M 10-Q · filed 2023-08-02 | |||
| 2022-03-31 | -$1.64M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $27.04M 10-K/A · filed 2023-03-30 | |||
| 2021-09-30 | $9.09M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $12.49M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | -$340.78K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $642.02K 10-K · filed 2022-03-22 | |||
| 2020-09-30 | $903.35K 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $1.25M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |